Savaysa (Edoxaban; Daiichi Sankyo) Drug Overview 2017/18-2026 - A Direct Oral Factor Xa Inhibitor Indicated for the Treatment and Prevention of DVT and PE - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: Savaysa" report has been added to ResearchAndMarkets.com's offering.

Savaysa (Edoxaban; Daiichi Sankyo) is a direct oral factor Xa inhibitor indicated for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Inhibition of factor Xa reduces thrombin generation and thrombus formation. Savaysa inhibits prothrombinase activity and thrombin-induced platelet aggregation, thus reducing blood clots.

Savaysa is also indicated for stroke prevention in atrial fibrillation.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Savaysa: Stroke Prevention in Atrial Fibrillation (SPAF)
  4. Savaysa: Venous Thromboembolism (VTE)

List of Figures

Figure 1: Savaysa for SPAF - SWOT analysis

Figure 2: Drug assessment summary of Savaysa for SPAF

Figure 3: Drug assessment summary of Savaysa for SPAF

Figure 4: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26

Figure 5: Savaysa for venous thromboembolism - SWOT analysis

Figure 6: Drug assessment summary of Savaysa for venous thromboembolism

Figure 7: Drug assessment summary Savaysa for venous thromboembolism

Figure 8: Savaysa sales forecast for VTE in the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Savaysa drug profile

Table 2: Savaysa pivotal trial data in SPAF

Table 3: Savaysa late-phase trial data in SPAF

Table 4: Savaysa ongoing late-phase clinical trials in SPAF

Table 5: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 6: Savaysa drug profile

Table 7: Savaysa pivotal trial data in venous thromboembolism

Table 8: Savaysa late-phase trial data in venous thromboembolism

Table 9: Savaysa ongoing late-phase clinical trial in venous thromboembolism

Table 10: Savaysa sales for VTE in the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/wxhmsd/savaysa?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs